generics

Interview With Gottlieb: A Discussion on Biosimilars, Opioids and Transparency
Interview With Gottlieb: A Discussion on Biosimilars, Opioids and Transparency
RAPS.org
FDA
Scott Gottlieb
biosimilars
generics
opioids
transparency
Flag link:
US Generic Drug Approvals Tick Upward in March and April
US Generic Drug Approvals Tick Upward in March and April
RAPS.org
generics
FDA
drug approvals
Flag link:
Challenged by generics industry, Maryland's drug pricing law found unconstitutional
Challenged by generics industry, Maryland's drug pricing law found unconstitutional
Fierce Pharma
Maryland
drug pricing
generics
Flag link:
Advent Is Said to Near Deal to Acquire Sanofi Generics Unit
Advent Is Said to Near Deal to Acquire Sanofi Generics Unit
Bloomberg
Advent International
Sanofi
generics
M&A
Flag link:
Teva's M&A-gone-wrong lawsuit over Rimsa deal nets a paltry settlement
Teva's M&A-gone-wrong lawsuit over Rimsa deal nets a paltry settlement
Fierce Pharma
Teva Pharmaceutical
generics
fraud
Rimsa
M&A
Flag link:
Eisai partners with Nichi-Iko in generics pact
Eisai partners with Nichi-Iko in generics pact
Biopharma Dive
Eisai
Nichi-Iko
generics
Flag link:
Drug Wars: Companies Fight Patents In Court With A Fortune At Stake
Drug Wars: Companies Fight Patents In Court With A Fortune At Stake
American Council on Science and Health
patents
generics
innovation
Flag link:
Impax reaches $20 mln deal to end trial over generic drug's delay
Impax reaches $20 mln deal to end trial over generic drug's delay
Yahoo/Reuters
Impax Labs
generics
Solodyn
Flag link:
Teva launches generic version of Shire's top-selling internal medicine
Teva launches generic version of Shire's top-selling internal medicine
Biopharma Dive
Teva Pharmaceutical
generics
Shire
Lialda
ulcerative colitis
Flag link:
The difficult momentum of Indian pharma sector
The difficult momentum of Indian pharma sector
GoinPharma
India
generics
Sun Pharma
Cipla
Dr Reddy's
Lupin
Flag link:
In a blow to its biggest revenue driver, Indivior loses patent battle with generics maker Alvogen
In a blow to its biggest revenue driver, Indivior loses patent battle with generics maker Alvogen
Endpoints
Indivior
patents
Suboxone
Alvogen
generics
Flag link:
Sanofi's for-sale generics unit is too pricey, or so says dropout bidder
Sanofi's for-sale generics unit is too pricey, or so says dropout bidder
Fierce Pharma
Sanofi
M&A
generics
Nordic Capital
Flag link:
Massachusetts court - Merck can be sued over generic drug injury
Massachusetts court - Merck can be sued over generic drug injury
Yahoo/Reuters
Merck
generics
Massachusetts
Flag link:
New FDA Generic Drug Reports Tabulate Approval Times
New FDA Generic Drug Reports Tabulate Approval Times
RAPS.org
FDA
generics
drug approvals
Flag link:
Teva takes issue with EC charges of pay-for-delay deal with Cephalon
Teva takes issue with EC charges of pay-for-delay deal with Cephalon
Seeking Alpha
Teva Pharmaceuticals
Europe
pay-for-delay
Cephalon
Provigil
generics
Flag link:
Amgen faces tough one-two blow as competition mounts for Repatha and Sensipar
Amgen faces tough one-two blow as competition mounts for Repatha and Sensipar
Fierce Pharma
Amgen
Repatha
Sensipar
generics
Sanofi
Regeneron
Praluent
Flag link:
GSK wins new reprieve as Hikma's generic Advair delayed again
GSK wins new reprieve as Hikma's generic Advair delayed again
Yahoo/Reuters
GSK
Hikma
generics
Advair
Flag link:
FDA Approves First Generic Versions of Amgen’s Sensipar
FDA Approves First Generic Versions of Amgen’s Sensipar
RAPS.org
FDA
generics
Amgen
Sensipar
Cipla
Aurobindo
Flag link:
Falloff in FDA Generic Drug Approvals Continues Into February
Falloff in FDA Generic Drug Approvals Continues Into February
RAPS.org
FDA
generics
drug approvals
Flag link:
Healthcare on the Hill - Increasing Competition in Pharmaceuticals Act
Healthcare on the Hill - Increasing Competition in Pharmaceuticals Act
CP Wire
competition
Healthcare on the Hill
FDA
generics
Flag link:

Pages